A new survey out by Myovant Sciences and Evidation is shining a spotlight on the crippling reality for women living with endometriosis or uterine fibroids.
Of those surveyed, more than 1 in 3 of those with endometriosis and almost 1 in 5 with uterine fibroids have considered quitting work or school due to the severity of their symptoms.
The survey collected data from 1,700 individuals using Evidation’s health platform. As part of National Women’s Health Week, Myovant, which markets Myfembree for both conditions with Pfizer, is sharing the survey results to demonstrate the serious impact that uterine fibroids and endometriosis can have on a person’s quality of life.
Uterine fibroids affect around 19 million women in the U.S., and 7.5 million suffer from endometriosis.
Specifically, 41% of respondents with one of the two ailments have missed work or school due to menstrual symptoms at least once every three menstrual cycles, versus 21% of respondents without a diagnosis.
In addition, as many as 21% of respondents with endometriosis and/or uterine fibroids also report being unable to do daily tasks outside of work every menstrual cycle, versus 12% of respondents without a diagnosis.
Other negative impacts include 16% of respondents reporting symptoms having an impact on work-related or school-related stress, and many reported that the symptoms affect their physical activity—taking fewer daily steps than those without a diagnosis.
“Millions suffer silently from endometriosis and uterine fibroids. Both diseases have excruciating impacts and insidious yet outsized effects in everyday life,” Christine Lemke, co-founder and CEO at Evidation, said in a press release.
“We are proud to partner with Myovant to ignite a conversation around how we can better understand and improve the daily health experiences of people with these conditions.”
This recent survey is the second collaboration between Myovant and Evidation. In 2019, the companies published "State of the Cycle" and continue to build on efforts to expand women’s health education and awareness.
Myovant is also a sponsor of the Fibroid Foundation’s Workplace Reset program and the Menstrual Equity Workplace Champion program launched in 2022.